Nerve growth factor in traumatic optic neuropathy
Descripción del Articulo
Traumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objecti...
Autores: | , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2023 |
Institución: | Universidad de San Martín de Porres |
Repositorio: | Horizonte médico |
Lenguaje: | español |
OAI Identifier: | oai:horizontemedico.usmp.edu.pe:article/2098 |
Enlace del recurso: | https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098 |
Nivel de acceso: | acceso abierto |
Materia: | nerve growth factor visual acuity optic nerve diseases wounds and injuries factor de crecimiento nervioso agudeza visual neuropatía óptica trauma |
id |
REVHM_0f0306c7f8ed8379c7eadf38d0513330 |
---|---|
oai_identifier_str |
oai:horizontemedico.usmp.edu.pe:article/2098 |
network_acronym_str |
REVHM |
network_name_str |
Horizonte médico |
repository_id_str |
|
dc.title.none.fl_str_mv |
Nerve growth factor in traumatic optic neuropathy Factor de crecimiento nervioso en neuropatía óptica traumática |
title |
Nerve growth factor in traumatic optic neuropathy |
spellingShingle |
Nerve growth factor in traumatic optic neuropathy Zea Quispe, Justiniano Oseas nerve growth factor visual acuity optic nerve diseases wounds and injuries factor de crecimiento nervioso agudeza visual neuropatía óptica trauma |
title_short |
Nerve growth factor in traumatic optic neuropathy |
title_full |
Nerve growth factor in traumatic optic neuropathy |
title_fullStr |
Nerve growth factor in traumatic optic neuropathy |
title_full_unstemmed |
Nerve growth factor in traumatic optic neuropathy |
title_sort |
Nerve growth factor in traumatic optic neuropathy |
dc.creator.none.fl_str_mv |
Zea Quispe, Justiniano Oseas Orihuela Echavigurin, Roberto Michael López Gonzales, Freddy Cristóbal |
author |
Zea Quispe, Justiniano Oseas |
author_facet |
Zea Quispe, Justiniano Oseas Orihuela Echavigurin, Roberto Michael López Gonzales, Freddy Cristóbal |
author_role |
author |
author2 |
Orihuela Echavigurin, Roberto Michael López Gonzales, Freddy Cristóbal |
author2_role |
author author |
dc.subject.none.fl_str_mv |
nerve growth factor visual acuity optic nerve diseases wounds and injuries factor de crecimiento nervioso agudeza visual neuropatía óptica trauma |
topic |
nerve growth factor visual acuity optic nerve diseases wounds and injuries factor de crecimiento nervioso agudeza visual neuropatía óptica trauma |
description |
Traumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objective of this study is to present the case of a patient who suffered fromTON and, at the same time, an asymmetrical bilateral condition, and was treated with nerve growth factor (NGF). This drug was the first to be discovered and demonstrate efficacy in maintaining the survival of central and peripheral neurons and facilitating their growth, differentiation and regeneration. A 13-year-old male patient attended the emergency room of Instituto Nacional de Ciencias Neurológicas and was later followed up at the Neuro-Ophthalmology Service. He was diagnosed with post-traumatic amaurosis caused by traumatic brain injury and epidural hematoma, and received two treatment cycles of NGF. After the first treatment cycle, hyporeactivity of both eyes occurred. And, at the end of the second treatment cycle, visual acuity improved significantly. NGF has been approved and marketed in China since 2015 and is a product thathas demonstrated its efficacy and safety in several clinical trials. Therefore, this study aims to make NGF a promising ITON treatment; in that sense, further clinical research is needed in this particular case. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-03 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098 10.24265/horizmed.2023.v23n1.09 |
url |
https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098 |
identifier_str_mv |
10.24265/horizmed.2023.v23n1.09 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1421 https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1441 https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1460 |
dc.rights.none.fl_str_mv |
Derechos de autor 2023 Horizonte Médico (Lima) https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Derechos de autor 2023 Horizonte Médico (Lima) https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/xml text/html |
dc.publisher.none.fl_str_mv |
Universidad de San Martín de Porres. Facultad de Medicina Humana |
publisher.none.fl_str_mv |
Universidad de San Martín de Porres. Facultad de Medicina Humana |
dc.source.none.fl_str_mv |
Horizonte Médico (Lima); Vol. 23 No. 1 (2023): January-March; e2098 Horizonte Médico (Lima); Vol. 23 Núm. 1 (2023): Enero-Marzo; e2098 Horizonte Médico (Lima); v. 23 n. 1 (2023): Enero-Marzo; e2098 2227-3530 1727-558X reponame:Horizonte médico instname:Universidad de San Martín de Porres instacron:USMP |
instname_str |
Universidad de San Martín de Porres |
instacron_str |
USMP |
institution |
USMP |
reponame_str |
Horizonte médico |
collection |
Horizonte médico |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1845989100401721344 |
spelling |
Nerve growth factor in traumatic optic neuropathyFactor de crecimiento nervioso en neuropatía óptica traumáticaZea Quispe, Justiniano Oseas Orihuela Echavigurin, Roberto Michael López Gonzales, Freddy Cristóbal nerve growth factorvisual acuityoptic nerve diseaseswounds and injuriesfactor de crecimiento nerviosoagudeza visualneuropatía ópticatraumaTraumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objective of this study is to present the case of a patient who suffered fromTON and, at the same time, an asymmetrical bilateral condition, and was treated with nerve growth factor (NGF). This drug was the first to be discovered and demonstrate efficacy in maintaining the survival of central and peripheral neurons and facilitating their growth, differentiation and regeneration. A 13-year-old male patient attended the emergency room of Instituto Nacional de Ciencias Neurológicas and was later followed up at the Neuro-Ophthalmology Service. He was diagnosed with post-traumatic amaurosis caused by traumatic brain injury and epidural hematoma, and received two treatment cycles of NGF. After the first treatment cycle, hyporeactivity of both eyes occurred. And, at the end of the second treatment cycle, visual acuity improved significantly. NGF has been approved and marketed in China since 2015 and is a product thathas demonstrated its efficacy and safety in several clinical trials. Therefore, this study aims to make NGF a promising ITON treatment; in that sense, further clinical research is needed in this particular case.La neuropatía óptica traumática (TON) es una entidad asociada al trauma facial y craneal, y constituye una causa importante para el desarrollo de la ceguera; es una complicación grave del trauma craneofacial que daña directa (dTON) o indirectamente (iTON) el nervio óptico (ON), cuya incidencia global de TON es de 0,7 a 2,5 %. El objetivo del presente estudio es presentar el caso de un paciente que padecía de TON y a la vez de una afección bilateral asimétrica, y que fue tratado con el factor de crecimiento nervioso mNGF. Este medicamento fue el primero que se descubrió y demostró eficacia en mantener la supervivencia de las neuronas centrales y periféricas y facilitar su crecimiento, diferenciación y regeneración. Se trata de un paciente de 13 años, sexo masculino, quien acude a la emergencia del Instituto Nacional de Ciencias Neurológicas y, posteriormente, su seguimiento clínico es por consultorio de Neuroftalmología, con un cuadrode amaurosis traumática, producto de un traumatismo encéfalo craneano con hematoma epidural, que recibió dos ciclos de tratamiento con factor de crecimiento nervioso. Luego del primer ciclo de tratamiento, se evidenció hiporreactividad de ambos ojos; al finalizar el segundo ciclo de tratamiento, se observó un aumento considerable de la agudeza visual. El mNGF está aprobado y comercializado en China desde el año 2015 y es un producto que ha demostrado su eficacia yseguridad en varios ensayos clínicos. Por ello, el presente estudio pretende convertir al factor de crecimiento nervioso como el tratamiento prometedor de iTON; en ese sentido, se necesita de amplias investigaciones clínicas en este caso enparticular.Universidad de San Martín de Porres. Facultad de Medicina Humana2023-03-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmltext/htmlhttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/209810.24265/horizmed.2023.v23n1.09Horizonte Médico (Lima); Vol. 23 No. 1 (2023): January-March; e2098Horizonte Médico (Lima); Vol. 23 Núm. 1 (2023): Enero-Marzo; e2098Horizonte Médico (Lima); v. 23 n. 1 (2023): Enero-Marzo; e20982227-35301727-558Xreponame:Horizonte médicoinstname:Universidad de San Martín de Porresinstacron:USMPspahttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1421https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1441https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/2098/1460Derechos de autor 2023 Horizonte Médico (Lima)https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:horizontemedico.usmp.edu.pe:article/20982023-03-03T14:48:39Z |
score |
13.37163 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).